Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Janux Therapeutics Inc (JANX)

Janux Therapeutics Inc (JANX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,839,276
  • Shares Outstanding, K 52,482
  • Annual Sales, $ 8,080 K
  • Annual Income, $ -58,290 K
  • EBIT $ -86 M
  • EBITDA $ -92 M
  • 60-Month Beta 3.29
  • Price/Sales 358.21
  • Price/Cash Flow N/A
  • Price/Book 4.39

Options Overview Details

View History
  • Implied Volatility 54.98% ( +6.71%)
  • Historical Volatility 134.05%
  • IV Percentile 3%
  • IV Rank 5.93%
  • IV High 203.77% on 02/23/24
  • IV Low 45.60% on 12/24/24
  • Put/Call Vol Ratio 0.18
  • Today's Volume 285
  • Volume Avg (30-Day) 1,911
  • Put/Call OI Ratio 0.46
  • Today's Open Interest 13,784
  • Open Int (30-Day) 20,497

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.46
  • Number of Estimates 6
  • High Estimate -0.35
  • Low Estimate -0.61
  • Prior Year -0.25
  • Growth Rate Est. (year over year) -84.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
40.02 +31.30%
on 12/02/24
71.71 -26.73%
on 12/05/24
+7.33 (+16.22%)
since 11/29/24
3-Month
40.02 +31.30%
on 12/02/24
71.71 -26.73%
on 12/05/24
+7.11 (+15.66%)
since 09/30/24
52-Week
7.79 +574.52%
on 02/05/24
71.71 -26.73%
on 12/05/24
+41.81 (+389.70%)
since 12/29/23

Most Recent Stories

More News
Why Janux Therapeutics Crushed the Market Today

News of an analyst's price-target hike plus a new round of capital-raising were the sparks that ignited Janux Therapeutics (NASDAQ: JANX) stock on Wednesday. The clinical-stage biotech's share price ended...

JANX : 52.70 (-2.59%)
JANX Stock Hits Record High on Prostate Cancer Study Data

Shares of Janux Therapeutics JANX surged 49% on Tuesday after the company posted updated interim results from a phase Ib study, which is evaluating JANX007 in patients with advanced or metastatic prostate...

JANX : 52.70 (-2.59%)
CSTL : 26.46 (-1.38%)
SPRO : 1.0050 (-2.43%)
Insider Sale: President and CEO of $JANX (JANX) Sells 15,000 Shares

David Alan Campbell, the President and CEO of $JANX ($JANX), sold 15,000 shares of the company on 12-03-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 5.8%...

JANX : 52.70 (-2.59%)
Stocks Settle Mixed as Nasdaq 100 Posts New Record High

The S&P 500 Index ($SPX ) (SPY ) Tuesday closed up +0.05%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.17%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.31%. Stocks on Tuesday...

JANX : 52.70 (-2.59%)
$SPX : 5,928.59 (-0.71%)
HON : 226.87 (-1.15%)
AXON : 603.53 (-1.22%)
TMDX : 59.37 (-2.70%)
$IUXX : 21,303.27 (-0.79%)
QQQ : 517.84 (-0.90%)
ZNH25 : 108-275 (+0.39%)
SYY : 76.48 (-0.61%)
T : 22.69 (-0.74%)
STX : 86.04 (-1.54%)
PG : 167.59 (-1.14%)
Janux Therapeutics Stock Hits 7-Month High On Prostate Cancer Drug Trial Data: Retail Confidence Spikes

The treatment, a tumor-activated T-cell engager, leverages the immune system by recruiting white blood cells to attack cancer cells.

JANX : 52.70 (-2.59%)
Stocks Weaken as T-note Yields Rise on US Labor Market Strength

The S&P 500 Index ($SPX ) (SPY ) today is down -0.22%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.25%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.23%. Stocks today are posting...

JANX : 52.70 (-2.59%)
CNP : 31.79 (-1.30%)
$SPX : 5,928.59 (-0.71%)
HON : 226.87 (-1.15%)
AXON : 603.53 (-1.22%)
TMDX : 59.37 (-2.70%)
$IUXX : 21,303.27 (-0.79%)
QQQ : 517.84 (-0.90%)
ZNH25 : 108-275 (+0.39%)
T : 22.69 (-0.74%)
STX : 86.04 (-1.54%)
X : 31.38 (+0.77%)
Stocks Pressured by Negative Corporate News

The S&P 500 Index ($SPX ) (SPY ) today is down -0.07%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.15%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.09%. Stocks today are slightly...

SYF : 65.28 (-0.97%)
JANX : 52.70 (-2.59%)
C : 70.59 (-0.58%)
$SPX : 5,928.59 (-0.71%)
HON : 226.87 (-1.15%)
SMCI : 31.23 (-2.35%)
LYV : 131.81 (-0.03%)
AXON : 603.53 (-1.22%)
TMDX : 59.37 (-2.70%)
$IUXX : 21,303.27 (-0.79%)
QQQ : 517.84 (-0.90%)
ZNH25 : 108-275 (+0.39%)
Insider Sale: President and CEO of $JANX (JANX) Sells 6,719 Shares

David Alan Campbell, the President and CEO of $JANX ($JANX), sold 6,719 shares of the company on 11-25-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 2.5%...

JANX : 52.70 (-2.59%)
5 Breakout Biotech Stocks Leading the Russell 2000 Higher

These small-cap biotech stocks are rallying hard in 2024, and still have room to keep leading the RUT higher.

JANX : 52.70 (-2.59%)
VKTX : 39.90 (-3.06%)
LBPH : 59.98 (+0.03%)
ARQT : 14.12 (-1.26%)
RNA : 28.45 (-5.51%)
Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb

/CNW/ -- In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of funding...

ONCY : 0.9303 (-6.39%)
CADL : 8.11 (-8.57%)
AZN : 65.60 (-1.00%)
HALO : 48.36 (+0.48%)
JANX : 52.70 (-2.59%)
ONC.TO : 1.34 (-6.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Janux Therapeutics Inc. is a biopharmaceutical company. It involved in developing novel T cell engager immunotherapies. Janux Therapeutics Inc. is based in LA JOLLA, Calif.

See More

Key Turning Points

3rd Resistance Point 57.02
2nd Resistance Point 56.20
1st Resistance Point 55.15
Last Price 52.70
1st Support Level 53.28
2nd Support Level 52.46
3rd Support Level 51.41

See More

52-Week High 71.71
Last Price 52.70
Fibonacci 61.8% 47.29
Fibonacci 50% 39.75
Fibonacci 38.2% 32.21
52-Week Low 7.79

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar